News | Spotlight

Press release from Companies

Published: 2019-10-31 11:36:58

Double Bond Pharmaceutical International AB: Euroresearch"s and Zoono"s products are now in Drugsson"s warehouse

Double Bond Pharmaceutical"s subsidiary Drugsson AB, distributor of Biopad, Biospray and a number of Biocide products (from Zoono) in the Nordic market, has received its deliveries of all products to Sweden. The products will be stored in stock. Biopad, Biospray is manufactured in Italy. The biocidal products are manufactured in New Zealand and imported via the UK. These are under registration in Sweden and will be available for the Swedish market shortly.

We are pleased that the products will be on sale shortly,” comments by Igor Lokot, CEO of Double Bond Pharmaceutical and Drugsson AB, - “We always continue to look for new, sought after products that may be of interest to Drugsson"s pipe-line”

More about Zoono: http://www.zoono.com

More about Euroresearch: http://www.euroresearch.biz

More about Drugsson AB: www.drugsson.com

___________________________________________________________________

Full Company Name: Double Bond Pharmaceutical International AB (publ)

Corporate identity: 556991-6082

Stock short name: DBP B

Share ISIN code: SE0007185525

For more info, contact

Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com

Follow us on LinkedIn (https://www.linkedin.com/company/double-bond-pharmaceutical?trk=co-feed-likes-one) and Twitter (https://twitter.com/DoubleBondPharm)!

_______________________________________________________________________________

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

Läs mer hos Cision
Read more about Double Bond Pharmaceutical International AB